Research ArticleBasic Science Investigations
Differential 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PET Responses to Pharmacologic Inhibition of the c-MET Receptor in Preclinical Tumor Models
Carleen Cullinane, Donna S. Dorow, Susan Jackson, Benjamin Solomon, Ekaterina Bogatyreva, David Binns, Richard Young, Maria E. Arango, James G. Christensen, Grant A. McArthur and Rodney J. Hicks
Journal of Nuclear Medicine August 2011, 52 (8) 1261-1267; DOI: https://doi.org/10.2967/jnumed.110.086967
Carleen Cullinane
Donna S. Dorow
Susan Jackson
Benjamin Solomon
Ekaterina Bogatyreva
David Binns
Richard Young
Maria E. Arango
James G. Christensen
Grant A. McArthur

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 52, Issue 8
August 1, 2011
Differential 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PET Responses to Pharmacologic Inhibition of the c-MET Receptor in Preclinical Tumor Models
Carleen Cullinane, Donna S. Dorow, Susan Jackson, Benjamin Solomon, Ekaterina Bogatyreva, David Binns, Richard Young, Maria E. Arango, James G. Christensen, Grant A. McArthur, Rodney J. Hicks
Journal of Nuclear Medicine Aug 2011, 52 (8) 1261-1267; DOI: 10.2967/jnumed.110.086967
Differential 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PET Responses to Pharmacologic Inhibition of the c-MET Receptor in Preclinical Tumor Models
Carleen Cullinane, Donna S. Dorow, Susan Jackson, Benjamin Solomon, Ekaterina Bogatyreva, David Binns, Richard Young, Maria E. Arango, James G. Christensen, Grant A. McArthur, Rodney J. Hicks
Journal of Nuclear Medicine Aug 2011, 52 (8) 1261-1267; DOI: 10.2967/jnumed.110.086967
Jump to section
Related Articles
Cited By...
- c-Met PET Imaging Detects Early-Stage Locoregional Recurrence of Basal-Like Breast Cancer
- PET of c-Met in Cancer with 64Cu-Labeled Hepatocyte Growth Factor
- Fluorodeoxyglucose-Based Positron Emission Tomography Imaging to Monitor Drug Responses in Solid Tumors
- Fluorodeoxyglucose-Based Positron Emission Tomography Imaging to Monitor Drug Responses in Hematological Tumors
- [18F]-FLT Positron Emission Tomography Can Be Used to Image the Response of Sensitive Tumors to PI3-Kinase Inhibition with the Novel Agent GDC-0941
- Crizotinib for the Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology
- 3'-Deoxy-3'-18F-Fluorothymidine PET/CT to Guide Therapy with Epidermal Growth Factor Receptor Antagonists and Bcl-xL Inhibitors in Non-Small Cell Lung Cancer